Each year, drugmakers lose their monopolies on a slate of big-selling old medicines. While top brands like Lyrica and Herceptin lost exclusivity last year—and more big rollouts are expected for 2021 and beyond—this year's exclusivity losses will cause some significant pain of their own.
